Latest Advances in the Development of CDK4/6 Inhibitors in HR+ Breast Cancer

November 27, 2017
Richard S. Finn, MD

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses advances in the development of CDK4/6 inhibitors for the treatment of hormone receptor (HR)-positive breast cancer.